Skip to main content

Necitumumab Side Effects

Medically reviewed by Drugs.com. Last updated on Sep 11, 2023.

Applies to necitumumab: intravenous solution.

Warning

Intravenous route (Solution)

Cardiopulmonary arrest and/or sudden death have been reported with necitumumab in combination with gemcitabine and cisplatin. Monitor serum electrolytes, including serum magnesium, potassium, and calcium. Hypomagnesemia has been reported with necitumumab plus gemcitabine and cisplatin. Monitor for hypomagnesemia, hypocalcemia, and hypokalemia prior to each necitumumab dose and for at least 8 weeks after discontinuation. Withhold treatment if grade 3 or 4 electrolyte abnormalities occur.

Serious side effects of Necitumumab

Along with its needed effects, necitumumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking necitumumab:

More common

Less common

Other side effects of Necitumumab

Some side effects of necitumumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to necitumumab: intravenous solution.

Cardiovascular

Common (1% to 10%): Venous thromboembolic events (VTE), arterial thromboembolic events (ATE), phlebitis

Frequency not reported: Cardiopulmonary arrest[Ref]

Dermatologic

Very common (10% or more): Rash (44%), dermatitis acneiform (15%)

Common (1% to 10%): Acne, pruritus, dry skin, skin fissures[Ref]

Gastrointestinal

Very common (10% or more): Vomiting (29%), diarrhea (16%), stomatitis (11%)

Common (1% to 10%): Dysphagia, mouth ulceration[Ref]

Local

Frequency not reported: Infusion related reactions[Ref]

Metabolic

Very common (10% or more): Hypomagnesemia (83%), hypocalcemia (45%), hypocalcemia (albumin corrected) (36%), hypophosphatemia (31%), hypokalemia (28%), weight loss (13%)[Ref]

Nervous system

Very common (10% or more): Headache (11%)

Common (1% to 10%): Dysgeusia[Ref]

Ocular

Common (1% to 10%): Conjunctivitis (includes conjunctivitis, eye irritation, vision blurred, conjunctivitis bacterial, dry eye, visual acuity reduced, blepharitis, allergic blepharitis, conjunctiva hemorrhage, eye infection, eye pain, lacrimation increased, ocular hyperemia, Sjogren's syndrome, visual impairment, and eye pruritus)

Frequency not reported: Eyelash trichomegaly[Ref]

Oncologic

Frequency not reported: Non-Squamous NSCLC -increased toxicity and increased mortality[Ref]

Respiratory

Very common (10% or more): Hemoptysis (10%)

Common (1% to 10%): Pulmonary embolism, epistaxis, oropharyngeal pain[Ref]

Hypersensitivity

Common (1% to 10%): Hypersensitivity reactions[Ref]

Immunologic

Common (1% to 10%): Paronychia[Ref]

Musculoskeletal

Common (1% to 10%): Muscle spasms[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection, dysuria[Ref]

Other

Common (1% to 10%): Pyrexia[Ref]

References

1. British Medical Association. Royal Pharmaceutical Society of Great Britain. Joint Formulary Committee. British National Formulary. http://bnf.org/bnf/ 2006.

2. Product Information. Portrazza (necitumumab). Eli Lilly and Company. 2015.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.